

Exhibit 1

Trudell Asset Purchase Agreement

[Filed at Docket No. 401]

Exhibit 2

Assumed Contracts Exhibit

[To Be Filed]

Exhibit 3

Transaction Steps Memorandum

Schedule 6.17(a) – Restructuring Transactions

Restructuring of intercompany receivables and payables between the Acquired Entities, Seller and Non-Debtors shall be implemented in three steps:

Step 1 (A)– Transfers of intercompany obligations to Vyaire Medical Inc. (“VMI”)

Step 1 (B) – Set-off of intercompany obligations

Step 2 – Transfer of MIM

Step 3 – Sale of RDx business

Assumptions

- All entities are tax resident only in their country of registration (for purposes of double tax treaties as well). There are no foreign permanent establishments for income tax purposes.
- All entities maintain sufficient substance in their country of registration (e.g. office space, own telephone number and email address as well as managing personnel).
- Tax capital contribution account of Vyaire Medical GmbH (“VMG”) as at December 31, 2021 amounts to approx. EUR 148m; tax equity of VMG as at December 31, 2021 amounts to approx. EUR 57m. It is assumed that the capital contribution account has not decreased materially since then.
- Tax issues outside the jurisdiction Germany have not been addressed.
- Tax implications other than the immediate German corporate income tax and trade tax implications of the contemplated measures of the Restructuring have not been discussed.
- VMG holds 100% of the shares in MIM Medizinische Instrumente und Monitoring GmbH (“MIM”), which is not Related to the Business. The carve-out of MIM from VMG shall occur by way of a sale and transfer of the shares in MIM to VMI at its fair market value (which is currently expected to be in the amount of approx. USD 30m).


Step 1 (A)– Transfers of IC Obligations to VMI

Step 1 (A)

- (i) For all pre-petition IC Obligations involving at least one non-U.S. Vyaire subsidiary (such as VMG):
- (a) one party will transfer the receivable (or payable) to VMI in exchange for a corresponding receivable from (or payable to) VMI; and
 - (b) with respect to any such payable transferred to VMI, the obligee on such transferred IC Obligation will enter into a novation to release the original obligor and make VMI the new obligor.

Following the transfers in Step 1 (A)(i), all IC Obligations of non-U.S. Vyaire subsidiaries will either be owed to, or owed from, VMI.


- (ii) For any IC Obligations between Vyaire Subsidiaries which will be sold as part of the RDx sale in Step 3:
- (a) one party will transfer the receivable (or payable) to VMG in exchange for a corresponding receivable from (or payable to) VMG; and
 - (b) with respect to any such payable transferred to VMI, the obligee on such transferred IC Obligation will enter into a novation to release the original obligor and make VMG the new obligor.



* for illustration purposes the above chart shows the relevant transfers of receivables/payable of VMG only (in essence for each non-U.S. Vyaire subsidiary the same measures and transfers occur).

Step 1 (B) – Set-off of IC Obligations**Step 1.(B)**

VMI will exercise set-off rights for all IC Obligations between itself and each respective Vyaire subsidiary (including VMG), such that, as a result, only a single payable or receivable in the amount of the net obligation will remain outstanding between VMI and each subsidiary (including VMG).




* for illustration purposes the above chart shows the relevant transfers of receivables/payable of VMG only (in essence for each non-U.S. Vyaire subsidiary the same measures and transfers occur).

Step 2 – Transfer of MIM

Step 2

VMI purchases 100% of the outstanding equity in MIM from VMG in satisfaction of a payable owed to Vyaire Medical, Inc. for \$[30M].*

***Note:** The purchase price will reflect the FMV of MIM, which depends on the FMV of MIM's assets (including Vents IP), existing liabilities (including tax and pension obligations), and value of any intercompany obligations. Depending on the FMV of MIM and the amount of the IC Obligation from VMG to VMI at the time of the exchange, the payable owed by VMG to VIM may be reduced to a small number or become a receivable.



NTD: For simplicity, certain Vyaire subsidiaries are not depicted on this slide.

Step 3 – Sale of RDx Business

Step 3 – At Closing:

(A) RDx Buyer purchases:

- (i) the RDx Assets from the applicable Vyaire subsidiaries for \$[●] cash;
- (ii) 100% of the outstanding equity in Vyaire Medical S.r.l. (Italy) from VIASYS Holdings Inc. (U.S.) for \$[●] cash;
- (iii) 100% of the outstanding equity in Vyaire Medical Pty. Ltd. (Australia) and Vyaire Medical Korea Ltd. (Korea) from Vyaire Medical Holdings B.V. (Netherlands) for \$[●] cash; and
- (iv) 100% of the outstanding equity in VMG from Breathe U.S. Holdings, LP (U.S.) for \$[●] cash.


- **(ii)** 100% of the outstanding equity in Vyair Medical S.r.l. (Italy) from VIASYS Holdings Inc. (U.S.) for \$[●] cash;

- (iii) 100% of the outstanding equity in Vyaire Medical Pty. Ltd. (Australia) and Vyaire Medical Korea Ltd. (Korea) from Vyaire Medical Holdings B.V. (Netherlands) for \$[●] cash; and

- **(iv)** 100% of the outstanding equity in VMG from Breathe U.S. Holdings, LP (U.S.) for \$[●] cash.

(D) If there remains any outstanding payable owed from VMVG to VMI, the RDx Buyer will make a capital contribution through a cash transfer to a bank account of VMVG in the course of the acquisition for \$[●] cash, which will be remitted through a cash transfer¹ to VMI in satisfaction of such obligation. Otherwise, any receivable owed from VMI to VMVG would be written off by VMVG.*

***Note:** In general, whether VMG is in a payable or receivable position with respect to VMI will depend on the FMV of MIM and the amount of the payable from VMG to VMI at the time of MIM's transfer in Step 2.



¹ NTD: Added per Deloitte's request.
NTD: For simplicity, certain Vyair subsidiaries are not depicted on this slide.

Annex – Overview of intercompany receivables / payables

[illegible]

Annex – Overview of intercompany receivables / payables – cont'd.

Name		Country		USD		June EDM		1,000		USD		Actions	
Company Number		Trading Partner - Plantul		Trading Partner		Other adjustments		FX		Total		Balance to VMI	
Select Entity Here>>>		Trading Partner - Plantul		Trading Partner		USD		USD		USD		pre Perimeter	
0120 - Vyair Medical Consumables, LLC	LC0724			US		(15,510,131)	66,459,622			50,949,491		(84,176,645)	(33,227,154)
0141 - Vyair Medical 211, Inc.				US		0				0		0	0
0143 - Vyair Medical 203, Inc.				US		0				0		0	0
0147 - Vyair Medical 207, Inc.				US		68,813,677	(68,813,677)			0		0	0
0150 - Vyair Medical ULC				Canada		0				0		0	0
0194 - Intermed Equipamento Medico Hospitalar LTDA				Brazil		1,129,559				1,129,559		(1,129,559)	0
0500 - Vyair Medical Pty Ltd.				Australia		(56,448)				(56,448)		56,448	0
0510 - Vyair Medical Pte. Ltd.				Singapore		(170,713)	(15,622)			(186,335)		186,335	0
0524 - Kingston Medical Device Trading (Shanghai) Co Ltd.				China		0				0		0	0
0524A - Kingston Medical Device Trading (Shanghai) Co Ltd.				China		(11,667,009)				(11,667,009)		11,667,009	0
0528 - Kingston Respiratory Malaysia 325 SDN. BHD				Malaysia		0				0		0	0
0531 - Vyair Medical Korea 334 Ltd.				Korea		0				0		0	0
0532 - IMT Medical Pte. Ltd.				Singapore		0				0		0	0
0532A - IMT Medical Pte. Ltd.				Singapore		0				0		0	0
0560 - Vyair Medical Turkey Tibbi Cihazlar Ticaret Anonim Sirketi				Turkey		0				0		0	0
0700 - Vyair Medical Products Limited				UK		(6,889,757)				(6,889,757)		6,889,757	0
0701 - Vyair Medical Holdings B.V.				Netherlands		0				0		0	0
0702 - CareFusion UK 232 Ltd.				UK		(3,460,919)				(3,460,919)		3,460,919	0
0703 - CareFusion UK 235 Limited				UK		(107,443)				(107,443)		107,443	0
0704 - Vyair Medical UK 236 Ltd.				UK		(5,015,384)				(5,015,384)		5,015,384	0
0715 - Vyair Respiratory Diagnostics LLC				US		0				0		0	0
0720 - Vyair GmbH				Germany		(1,256,477)				(1,256,477)		1,256,477	0
0722 - Vyair Medical International B.V.				Netherlands		0				0		0	0
0723 - Vyair Medical Cooperatief U.A.				Netherlands		0				0		0	0
0724 - Vyair Medical Germany 234 GmbH				Germany		(953,186)				(953,186)		953,186	0
0725 - MM Medizintechnik Instr. Monitoring GmbH				Germany		(2,433,846)				(2,433,846)		2,433,846	0
0726 - Advanced Respiratory Care AG				Switzerland		0				0		0	0
0727 - Acutronic Medical Systems AG				Switzerland		3,657,333				3,657,333		(3,657,333)	0
0729 - Imimedical AG				Switzerland		1,116,377				1,116,377		(1,116,377)	0
0730 - Vyair Medical AB				Sweden		13,957				13,957		(13,957)	0
0735 - Vyair BV				Netherlands		143,215				143,215		(143,215)	0
0760 - Vyair S.r.l. Italy				Italy		(52,589)				(52,589)		52,589	0
0762 - Vyair Medical Netherlands 238 BV				Netherlands		(12,409,791)				(12,409,791)		12,409,791	0
0765 - Vyair Finance B.V.				Netherlands		(42,275,130)				(42,275,130)		42,275,130	0
0785 - Vyair Medical Sarl				Switzerland		0				0		0	0
0785A - Vyair Medical Sarl				Switzerland		(3,892)				(3,892)		3,892	0
8785 - Vyair Medical Sarl				Switzerland		(427,664)				(427,664)		427,664	0
0800 - Vyair Medical 323 DMCC				Dubai		0				0		0	0
8590 - Vyair Medical Private Limited				India		(94,200)				(94,200)		94,200	0
8737 - Vyair Medical Denmark, Filial of Vyair Medical AB (Denmark Branch)				Denmark		1,114				1,114		(1,114)	0
8763 - Vyair Medical Italy 237 Srl				Italy		(1,639,582)				(1,639,582)		1,639,582	0

Exhibit 4

Holdback Schedule

Estimated Holdback Schedule

Holback Details			
(\$ millions)	Est. Amts. - US	Est. Amts. - International	Est. Amts. - Total
Estimated Employee Related Costs	\$ (4.5)	\$ (4.2)	\$ (8.7)
Estimated Post-Petition AP & 503(b)(9) Claims	(1.3)	-	(1.3)
Estimated Tax	(0.8)	(5.2)	(6.0)
Estimated Wind Down and Other Expenses	(6.4)	(2.7)	(9.1)
Total	\$ (13.0)	\$ (12.1)	\$ (25.1)